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The risk of genetically modified organisms (GMOs) and
foods derived from GMOs for human health and parti-
cularly their allergenicity must be assessed before they
are authorized to be put on the market in the European
Union. Data from the studies performed by the Appli-
cant are evaluated by the GMO Panel of the European
Food Safety Authority (EFSA). It then publishes a scien-
tific opinion including a conclusion on the food safety
for the information of the Risk Manager (i.e. the Eur-
opean Commission).
Recommendations for allergenicity assessment have
been provided by international scientific committees and
particularly by EFSA in recent reports. Both the risk of
de novo sensitization of genetically predisposed consu-
mers and of elicitation of an allergic reaction in consu-
mers already sensitized (e.g. to cross reacting allergens)
must be assessed on a case by case basis. Two issues
must be addressed :
i) The allergenicity of the newly expressed protein(s)
encoded by the transgene inserted in the GMO. The
assessment is based on the so called weight of evidence
approach because no characteristics can allow to defi-
nitely predict the (absence of) allergenicity of a protein.
Information of different nature including origin, struc-
ture, immunological and physico chemical properties of
the protein, obtained using in silico, in vitro and possibly
in vivo tests are considered to conclude on the likeli-
hood of allergenicity.
ii) The allergenicity of the whole GM food. Applicant
must test that no unintended effect of the genetic modifi-
cation, e.g. resulting in an over-expression of endoge-
neous allergen(s), has occurred by comparing the allergen
repertoire of the GMO and its non GM counterpart.
This may be performed by profiling methodologies using
–omics technologies, generally in association with the use
of allergic human sera as probes.
For both cases, scientific grounds for the design and
interpretation of strategies and testing methods that
may be used on a case by case basis will be discussed in
the presentation.
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